BridgeBio Pharma
BBIO
Market cap $8.82B

46.47 USD

+0.20

0.43%

At close Jul 11, 4:00 PM EDT

After hours

46.47

+0.00

0.00%

1 day

0.43%

5 days

6.17%

1 month

19.00%

3 months

37.04%

6 months

37.77%

Year to date

64.79%

1 year

72.82%

5 years

55.78%

10 years

68.68%

About: BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Employees: 730

Healthcare Biotechnology

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 9 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

489% more call options, than puts

Call options by funds: $472M | Put options by funds: $80.1M

143% more first-time investments, than exits

New positions opened: 73 | Existing positions closed: 30

53% more repeat investments, than reductions

Existing positions increased: 119 | Existing positions reduced: 78

32% more capital invested

Capital invested by funds: $4.85B [Q4 2024] → $6.41B (+$1.56B) [Q1 2025]

20% more funds holding in top 10

Funds holding in top 10: 15 [Q4 2024] → 18 (+3) [Q1 2025]

15% more funds holding

Funds holding: 262 [Q4 2024] → 301 (+39) [Q1 2025]

3.88% more ownership

Funds ownership: 93.48% [Q4 2024] → 97.36% (+3.88%) [Q1 2025]

See Fund Rankings

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$49

5%

upside

Avg. target

$61

32%

upside

High target

$76

64%

upside

9 analyst ratings

9 positive

100%

0 neutral

0%

0 negative

0%

Citigroup David Lebowitz	44%upside $67	Buy Maintained	11 Jul 2025
Oppenheimer Leland Gershell	29%upside $60	Outperform Upgraded	9 Jul 2025
Wells Fargo Tiago Fauth	64%upside $76	Overweight Maintained	30 Jun 2025
B of A Securities Geoff Meacham	16%upside $54	Buy Maintained	25 Jun 2025
Wolfe Research Andy Chen	5%upside $49	Outperform Initiated	17 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about BBIO published over the past 30 days

CNBC Television

It is time for a move higher in biotech, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.

It is time for a move higher in biotech, says Mizuho's Jared Holz

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

PALO ALTO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced it has sold a portion of royalties due to the Company from sales of BEYONTTRA in Europe to HealthCare Royalty (“HCRx”) and funds managed by Blue Owl Capital (“Blue Owl”) for $300 million. This royalty financing agreement monetizes select anticipated royalties and provides immediate less-dilutive capital to the Company.

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, July 11, 2025 at 8:00 am ET with Matthew Wicklund, M.D., FAAN, Professor of Neurology and Vice Chair for Research, Department of Neurology at the University of Texas (UT) Health Science Center San Antonio.

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

BridgeBio: New Data Bolsters The Bull Case

BridgeBio's Attruby launch crushed expectations, with Q1 revenue triple analyst estimates, driven by higher-than-expected conversion rates and minimal free trial usage. Competitive threats from Amvuttra appear overstated, as Attruby script declines were minor and BridgeBio management remains confident in market positioning and pricing. My updated model projects 2025 revenues of $728 million, far above consensus, and sees potential for nearly $1 billion in 2026 from existing patients alone.

BridgeBio: New Data Bolsters The Bull Case

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, FL on Monday, June 9 at 8:40 am ET.

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

- In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence of new-onset AF/AFL by 17% in the subgroup with no prior history of AF compared to placebo

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

- For each 5-mg/dL increase in serum TTR level within 28 days of starting treatment, the relative risk reduction of mortality was up to 31.6% through Month 30, confirming the hypothesis that ever better levels of stabilization achieved by treatment with acoramidis, a near-complete (≥90%) TTR stabilizer, lead to ever better clinical outcomes

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on May 9, 2025, the compensation committee of BridgeBio's board of directors approved equity grants to 36 new employees in restricted stock units for an aggregate of 101,974 shares of the Company's common stock.

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 63.9% in BridgeBio Pharma (BBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

- ATTRibute-CM, BridgeBio's Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients (59.1% risk reduction) , establishing the mechanistic hypothesis that stabilizing TTR may delay or prevent ATTRv-CM

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

See News Rankings

Charts implemented using Lightweight Charts™